Frontiers in Oncology | Pharmacology of Anti-Cancer Drugs

Review

Published on 30 Jul 2025

Synergistic strategies in photodynamic combination therapy for cancer: mechanisms, nanotechnology, and clinical translation

in Pharmacology of Anti-Cancer Drugs

Daohong Kan
Rong Ding
Huchuan Yang
Yuming Jia
Kaijian Lei
Zhongming Wang
Wei Zhang
Chaokun Yang
Zongjunlin Liu
Fang Xie

Frontiers in Oncology

doi 10.3389/fonc.2025.1607259

206 views

Original Research

Published on 30 Jul 2025

PD-L1 expression in microvascular endothelial cells predicts the efficacy and side effects of anlotinib

in Pharmacology of Anti-Cancer Drugs

Yingfang Feng
Yuan Gao
Shaochuan Liu
Tingting Qin
Yan Zhang
Jing Wang
Kai Li

Frontiers in Oncology

doi 10.3389/fonc.2025.1544278

327 views

Original Research

Accepted on 29 Jul 2025

Negative Outcomes Associated with Tyrosine Kinase Inhibitors During Management of Gastrointestinal Stromal Tumors: Examination of Data from the FDA Adverse Event Reporting System

in Pharmacology of Anti-Cancer Drugs

Yuxuan Ma
Ahui Fan
Yuhao Wang
Xu Shenhui
Xin Liu
Jianjun Yang

Frontiers in Oncology

doi 10.3389/fonc.2025.1608451

Original Research

Accepted on 28 Jul 2025

Adverse events of pexidartinib for the treatment of TGCT: A real-world disproportionality analysis using FDA Adverse Event Reporting System database

in Pharmacology of Anti-Cancer Drugs

Yu Lin
Xinlei Zheng
Li Lin
Maohua Chen

Frontiers in Oncology

doi 10.3389/fonc.2025.1594585

Case Report

Accepted on 24 Jul 2025

Acute thrombocytopenia and fibrinogen reduction occurring after Nintedanib treatment for immune checkpoint inhibitor-related pneumonia: a case report

in Pharmacology of Anti-Cancer Drugs

Jian Zheng
Nan Zhou
Dexiang Pang

Frontiers in Oncology

doi 10.3389/fonc.2025.1561440

160 views

Review

Accepted on 22 Jul 2025

CHEMOTERAPEUTIC NANOPARTICLES FOR GLIOBLASTOMA

in Pharmacology of Anti-Cancer Drugs

Samantha Messina
Candida Zuchegna
Mara Bruzzi

Frontiers in Oncology

doi 10.3389/fonc.2025.1641752

121 views

Editorial

Published on 17 Jul 2025

Editorial: Safety consideration in the development of anti-tumor monoclonal antibodies during drug development

in Pharmacology of Anti-Cancer Drugs

Tao Wang
Shaad Essa Abedin
Jan Willem van der Laan

Frontiers in Oncology

doi 10.3389/fonc.2025.1640377

529 views

Systematic Review

Published on 17 Jul 2025

A bibliometric and visual analysis of Jak1 to explore trends and frontiers

in Pharmacology of Anti-Cancer Drugs

Cong Yu
Jiamin Cao
Xiaodong Xie
Wenguang Chen
Ensi Hong

Frontiers in Oncology

doi 10.3389/fonc.2025.1537508

462 views

Original Research

Published on 17 Jul 2025

Immune checkpoint inhibitor-associated autoimmune encephalitis and other neurological immune-mediated adverse events: a pharmacovigilance study using the FAERS and JADER

in Pharmacology of Anti-Cancer Drugs

Xiaomeng Di
Xiaohong Shi
Feng Gai
Jiawei Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1621045

550 views

Original Research

Published on 16 Jul 2025

Utilization of dexrazoxane in patients treated with doxorubicin: a retrospective, propensity matched analysis of cardiac function and toxicity

in Pharmacology of Anti-Cancer Drugs

Zachary M. Neiman
Carlo S. Legasto
Alan K. Chin
Tiffany Guan
Brian C. Schulte

Frontiers in Oncology

doi 10.3389/fonc.2025.1621409

599 views

Review

Published on 16 Jul 2025

M6A RNA modification: focusing on non-small cell lung cancer progression, therapeutic strategies and challenges

in Pharmacology of Anti-Cancer Drugs

Yuyang Yan
Jiarui Yin
Quan Ding
Yan Lu
Shuhua Gou
Xi Xu
Yulin Li

Frontiers in Oncology

doi 10.3389/fonc.2025.1622359

580 views

Review

Accepted on 14 Jul 2025

cGAS-STING signal status after EGFR-TKIs resistance in Non-Small Cell Lung Cancer

in Pharmacology of Anti-Cancer Drugs

Fang Hao

Frontiers in Oncology

doi 10.3389/fonc.2025.1643349

262 views

Original Research

Accepted on 14 Jul 2025

Integrating Network Pharmacology and Transcriptomics to Identify Solasonine's Anti-Osteosarcoma Targets and Experimental Validation

in Pharmacology of Anti-Cancer Drugs

Daihao Wei
Minyu Li
Dawei Chu
Jiandang Shi

Frontiers in Oncology

doi 10.3389/fonc.2025.1614058

113 views

Original Research

Published on 11 Jul 2025

AMPs inhibit the proliferation, migration, and invasion of lung cancer via the CHRM3/PI3K/AKT and CHRM3/MAPK pathways

in Pharmacology of Anti-Cancer Drugs

Jun Wu
Congcong Huang
Shangning Wang
Liuyan Chen
Quan Cheng
Shao Zhang

Frontiers in Oncology

doi 10.3389/fonc.2025.1582040

692 views

Original Research

Published on 08 Jul 2025

Cell-in-cell associated lncRNA signature predicts prognosis and immunotherapy response in gastric cancer

in Pharmacology of Anti-Cancer Drugs

Junzuo Lin
Liancheng Wu
Zhengfei Zhao

Frontiers in Oncology

doi 10.3389/fonc.2025.1597187

785 views

Original Research

Published on 18 Jun 2025

The anti-inflammatory effects of oridonin in resisting esophageal cancer

in Pharmacology of Anti-Cancer Drugs

Mengfan Peng
Xiaofang Zhang
Lei Yang
Baosong Liu

Frontiers in Oncology

doi 10.3389/fonc.2025.1585057

1,050 views